167 related articles for article (PubMed ID: 33546945)
1. PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction.
Zeller M; Lambert G; Farnier M; Maza M; Nativel B; Rochette L; Vergely C; Cottin Y
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):880-885. PubMed ID: 33546945
[TBL] [Abstract][Full Text] [Related]
2. Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.
Gao J; Yang YN; Cui Z; Feng SY; Ma J; Li CP; Liu Y
Lipids Health Dis; 2021 May; 20(1):56. PubMed ID: 34044829
[TBL] [Abstract][Full Text] [Related]
3. Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort.
Gao Y; Qiu Y; Wu J; Diao W; Zhang H; Wang S; Du Z; Dong J; Zhang M; Jiang L
Cardiology; 2018; 141(2):88-97. PubMed ID: 30423567
[TBL] [Abstract][Full Text] [Related]
4. [Predictive value of plasma PCSK9 levels in acute myocardial infarction patients without reperfusion therapy for recurrence of cardiovascular events within 1 year].
Gao Y; Zhang HB; Hou LL; Wang SM
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(35):2750-2755. PubMed ID: 31550797
[No Abstract] [Full Text] [Related]
5. The relationship between protein convertase subtilisin kexin type-9 levels and extent of coronary artery disease in patients with non-ST-elevation myocardial infarction.
Dalgic Y; Abaci O; Kocas C; Cetinkal G; Dalgic SN; Buyuk A; Ser OS; Batit S; Arat A; Gurmen AT
Coron Artery Dis; 2020 Jan; 31(1):81-86. PubMed ID: 31206403
[TBL] [Abstract][Full Text] [Related]
6. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
[TBL] [Abstract][Full Text] [Related]
7. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.
Cariou B; Guérin P; Le May C; Letocart V; Arnaud L; Guyomarch B; Pichelin M; Probst V
Diabetes Metab; 2017 Dec; 43(6):529-535. PubMed ID: 28865748
[TBL] [Abstract][Full Text] [Related]
8. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
[TBL] [Abstract][Full Text] [Related]
9. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
Rasmussen LD; Bøttcher M; Ivarsen P; Jørgensen HS; Nyegaard M; Buttenschøn H; Gustafsen C; Glerup S; Bøtker HE; Svensson M; Winther S
Nephrol Dial Transplant; 2020 Apr; 35(4):632-639. PubMed ID: 30137516
[TBL] [Abstract][Full Text] [Related]
10. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
[TBL] [Abstract][Full Text] [Related]
11. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.
Almontashiri NA; Vilmundarson RO; Ghasemzadeh N; Dandona S; Roberts R; Quyyumi AA; Chen HH; Stewart AF
PLoS One; 2014; 9(9):e106294. PubMed ID: 25180781
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.
Li JJ; Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q
Medicine (Baltimore); 2015 Dec; 94(52):e2426. PubMed ID: 26717403
[TBL] [Abstract][Full Text] [Related]
13. Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
Nose D; Shiga Y; Ueda Y; Idemoto Y; Tashiro K; Suematsu Y; Kuwano T; Kitajima K; Saku K; Miura SI
Heart Vessels; 2019 Jan; 34(1):19-28. PubMed ID: 29974199
[TBL] [Abstract][Full Text] [Related]
14. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
[TBL] [Abstract][Full Text] [Related]
15. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Hu D; Yang Y; Peng DQ
Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
[TBL] [Abstract][Full Text] [Related]
16. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Ridker PM; Rifai N; Bradwin G; Rose L
Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
Panahi Y; Ghahrodi MS; Jamshir M; Safarpour MA; Bianconi V; Pirro M; Farahani MM; Sahebkar A
Clin Biochem; 2019 Dec; 74():12-18. PubMed ID: 31493378
[TBL] [Abstract][Full Text] [Related]
18. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
[TBL] [Abstract][Full Text] [Related]
19. Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
Liberale L; Carbone F; Bertolotto M; Bonaventura A; Vecchié A; Mach F; Burger F; Pende A; Spinella G; Pane B; Camici GG; Palombo D; Dallegri F; Montecucco F
Int J Cardiol; 2018 Jul; 263():138-141. PubMed ID: 29754909
[TBL] [Abstract][Full Text] [Related]
20. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.
Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
Cardiovasc Diabetol; 2020 Oct; 19(1):167. PubMed ID: 33023603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
